Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.

Cell reports - 14 Dec 2021

McFall Thomas, Stites Edward C

Abstract excerpt

Mutations can be important biomarkers that influence the selection of specific cancer treatments. We recently combined mathematical modeling of RAS signaling network biochemistry with experimental cancer cell biology to determine why KRAS G13D is a biomarker for sensitivity to epidermal growth factor receptor (EGFR)-targeted therapies. The critical mechanistic difference between KRAS G13D and the other most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Colorectal Neoplasms
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Mutation

Share to Protein Kinase Inhibitors

Share to ras Proteins

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 34910921
DOI: 10.1016/j.celrep.2021.110096
PMCID: PMC8867612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.PMID 34910921Read ↗

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.Semantic proximity Read ↗

A systems mechanism for KRAS mutant allele–specific responses to targeted therapySemantic proximity Read ↗

A quantitative systems pharmacology analysis of KRAS G12C covalent inhibitorsSemantic proximity Read ↗

Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.Semantic proximity Read ↗

Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.Semantic proximity Read ↗

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in PatientsSemantic proximity Read ↗

Integrating computational chemistry and machine learning to predict KRAS mutation-induced resistanceSemantic proximity Read ↗

New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.Semantic proximity Read ↗

Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational LandscapeSemantic proximity Read ↗

A computational panel of pathological RAS mutants with implications for personalized medicine and genetic medicineSemantic proximity Read ↗

Mechanistic modeling to investigate signaling by oncogenic Ras mutants.Semantic proximity Read ↗

NMR-based functional profiling of RASopathies and oncogenic RAS mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.